CL2024002309A1 - Métodos de tratamiento usando nivel de p-tau181. - Google Patents
Métodos de tratamiento usando nivel de p-tau181.Info
- Publication number
- CL2024002309A1 CL2024002309A1 CL2024002309A CL2024002309A CL2024002309A1 CL 2024002309 A1 CL2024002309 A1 CL 2024002309A1 CL 2024002309 A CL2024002309 A CL 2024002309A CL 2024002309 A CL2024002309 A CL 2024002309A CL 2024002309 A1 CL2024002309 A1 CL 2024002309A1
- Authority
- CL
- Chile
- Prior art keywords
- tau181
- level
- treatment methods
- methods
- suspected
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306060P | 2022-02-02 | 2022-02-02 | |
| US202263269394P | 2022-03-15 | 2022-03-15 | |
| US202263364617P | 2022-05-12 | 2022-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002309A1 true CL2024002309A1 (es) | 2025-01-24 |
Family
ID=84488881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002309A CL2024002309A1 (es) | 2022-02-02 | 2024-07-31 | Métodos de tratamiento usando nivel de p-tau181. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250377367A1 (https=) |
| EP (1) | EP4473009A1 (https=) |
| JP (1) | JP2025506389A (https=) |
| KR (1) | KR20240142535A (https=) |
| AU (1) | AU2022439338A1 (https=) |
| CA (1) | CA3243435A1 (https=) |
| CL (1) | CL2024002309A1 (https=) |
| IL (1) | IL314581A (https=) |
| MX (1) | MX2024009492A (https=) |
| TW (1) | TW202339794A (https=) |
| WO (1) | WO2023149970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025260029A1 (en) * | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210324056A1 (en) * | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| KR20220084095A (ko) * | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
-
2022
- 2022-11-09 AU AU2022439338A patent/AU2022439338A1/en active Pending
- 2022-11-09 CA CA3243435A patent/CA3243435A1/en active Pending
- 2022-11-09 IL IL314581A patent/IL314581A/en unknown
- 2022-11-09 WO PCT/US2022/079571 patent/WO2023149970A1/en not_active Ceased
- 2022-11-09 US US18/835,235 patent/US20250377367A1/en active Pending
- 2022-11-09 MX MX2024009492A patent/MX2024009492A/es unknown
- 2022-11-09 EP EP22822805.2A patent/EP4473009A1/en active Pending
- 2022-11-09 KR KR1020247029332A patent/KR20240142535A/ko active Pending
- 2022-11-09 TW TW111142860A patent/TW202339794A/zh unknown
- 2022-11-09 JP JP2024545951A patent/JP2025506389A/ja active Pending
-
2024
- 2024-07-31 CL CL2024002309A patent/CL2024002309A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240142535A (ko) | 2024-09-30 |
| TW202339794A (zh) | 2023-10-16 |
| CA3243435A1 (en) | 2023-08-10 |
| JP2025506389A (ja) | 2025-03-11 |
| US20250377367A1 (en) | 2025-12-11 |
| AU2022439338A1 (en) | 2024-08-15 |
| MX2024009492A (es) | 2024-08-09 |
| WO2023149970A1 (en) | 2023-08-10 |
| IL314581A (en) | 2024-09-01 |
| EP4473009A1 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000063A1 (es) | Biomarcadores para el tratamiento de la enfermedad de alzheimer | |
| CL2024002309A1 (es) | Métodos de tratamiento usando nivel de p-tau181. | |
| MX2025005880A (es) | Metodos de tratamiento que usan un nivel de tomografia de emision de positrones (pet) de tau | |
| Pasternak et al. | Advances in microstructural diffusion neuroimaging for psychiatric disorders | |
| Mao et al. | Decreased activation of cingulo-frontal-parietal cognitive/attention network during an attention-demanding task in patients with chronic low back pain | |
| EA202192260A1 (ru) | Биомаркеры циклин-зависимой киназы 2 и их применение | |
| CY1118660T1 (el) | Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων | |
| CR8230A (es) | Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado y sondas para diagnostico de ovillos neuro fibrilares yagentes... | |
| Kim et al. | Topographic pattern of cortical thinning with consideration of motor laterality in Parkinson disease | |
| CL2023001600A1 (es) | Biomarcadores del agonista de trem2 y métodos para su uso | |
| BR112022014553A2 (pt) | Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic | |
| CR20230121A (es) | Tratamiento de la enfermedad de parkinson | |
| EA202192176A1 (ru) | Нарушения, опосредованные интерфероном i типа | |
| WO2023129531A3 (en) | Methods for diagnosing and/or treating alzheimer's disease | |
| JOP20210009A1 (ar) | طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله | |
| MX2023014113A (es) | Biomarcadores agonistas de trem2 y métodos para usarlos. | |
| MX2024009597A (es) | Imagenologia de tau regional para diagnosticar y tratar la enfermedad de alzheimer. | |
| MX2025014802A (es) | Metodos de tratamiento mediante el uso de un anticuerpo anti protofibrillas de peptido beta-amiloide (abeta) | |
| MX2023014341A (es) | Tratamiento de la enfermedad cerebrovascular con agentes de la proteina 3 homologa de notch del locus neurogenico (notch3). | |
| Saez-Clarke et al. | Distress tolerance and perceived cancer-related cognitive impairment in nonmetastatic breast cancer. | |
| Nehra et al. | Indian Aphasia battery: Tool for specific diagnosis of language disorder post stroke | |
| Lee et al. | Effects of community-dwelling older adults’ demographics and social, mental, and physical functions on depressive disorder | |
| Chitradevi et al. | Brain hemisphere analysis using genetic algorithm and fuzzy clustering in Alzheimer disease | |
| Qin et al. | Divergent amygdala function in proposed brain-first and body-first Parkinson's disease: A resting-state functional magnetic resonance imaging study | |
| MX2026000543A (es) | Peptidos antimicrobianos |